Dapagliflozin and Metformin Hydrochloride
Brand Names: Xigduo
Methodology & AI Transparency ⓘ
Dapagliflozin and Metformin Hydrochloride Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: As a federal NDC-monographed biguanide (42571-322, 63304-026, manufactured/labeled by Micro Labs Limited), Dapagliflozin and Metformin Hydrochloride provides oral-route dosing across 5 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release and 5 mg/1 / 500 mg/1 Tablet, Film Coated, Extended Release under licensed medical supervision.
- 2 Real-world patient consensus: Zero-PHI community consensus: 78% favorable across 16 logged regimens (Xigduo).
- 3 Typical cash cost range: 30-day cash pricing ranges from $27.16 discount cash to $66.54 walk-in retail (NADAC $0.4606/unit).
- 4 Top reported side effects / signs: Most commonly reported Dapagliflozin and Metformin Hydrochloride tolerability events: nausea (8.5%), headache (7.1%), dizziness (6.2%).
Ask our AI Specialists anything about Dapagliflozin and Metformin Hydrochloride
Dapagliflozin and Metformin Hydrochloride Mechanism, CYP450 Pathways & DailyMed Monograph
As a federal NDC-monographed biguanide (42571-322, 63304-026, manufactured/labeled by Micro Labs Limited), Dapagliflozin and Metformin Hydrochloride provides oral-route dosing across 5 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release and 5 mg/1 / 500 mg/1 Tablet, Film Coated, Extended Release under licensed medical supervision.
Acting as a oral-route biguanide moiety, Dapagliflozin and Metformin Hydrochloride (NDC 42571-322, 63304-026, manufactured/labeled by Micro Labs Limited) regulates downstream signaling pathways proportional to 5 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release and 5 mg/1 / 500 mg/1 Tablet, Film Coated, Extended Release titration and patient renal/hepatic reserve.
Pharmacokinetic profiling of Dapagliflozin and Metformin Hydrochloride demonstrates an elimination half-life of Mean elimination half-life of 4 to 12 hours across adult Dapagliflozin and Metformin Hydrochloride dosing with Oral fraction absorbed ranges from 70% to 82% (Dapagliflozin and Metformin Hydrochloride 5) systemic bioavailability; clearance proceeds via dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of dapagliflozin and metformin hydrochloride, reaching clinical onset within oral tmax achieved within 2 to 3 hours following dapagliflozin and metformin hydrochloride ingestion.
Titration schedules for Dapagliflozin and Metformin Hydrochloride (5 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release → 5 mg/1 / 500 mg/1 Tablet, Film Coated, Extended Release → 10 mg/1 / 500 mg/1 Tablet, Film Coated, Extended Release → 10 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release → 10 mg/1 / 500 mg/1 Tablet, Extended Release) require excluding confirmed ige-mediated allergy or cutaneous reaction to dapagliflozin and metformin hydrochloride (dapagliflozin and metformin hydrochloride) components; uncompensated hepatic or renal insufficiency incompatible with dapagliflozin and metformin hydrochloride (5 mg/1 / 1000 mg/1 tablet, film coated, extended release) clearance; real-world patient logs highlight nausea (8.5% of reports), headache (7.1% of reports), dizziness (6.2% of reports) alongside a 78.00% Worth-It consensus.
Reconcile eGFR-adjusted medications before escalating Dapagliflozin and Metformin Hydrochloride in polypharmacy regimens.
Alcohol or high-fat meal timing can shift absorption rate and orthostatic tolerance during Dapagliflozin and Metformin Hydrochloride dosing.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Confirmed IgE-mediated allergy or cutaneous reaction to Dapagliflozin and Metformin Hydrochloride (Dapagliflozin and Metformin Hydrochloride) components
- Uncompensated hepatic or renal insufficiency incompatible with Dapagliflozin and Metformin Hydrochloride (5 mg/1 / 1000 mg/1 Tablet, Film Coated, Extended Release) clearance
Logged Side-Effect Incidence (16 Reports)
Dapagliflozin and Metformin Hydrochloride Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Dapagliflozin and Metformin Hydrochloride)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Urinary tract infections in patients with diabetes treated with: What a 3,152-Participant Study Found Treatment of type 2 diabetes with once-daily dapagliflozin 5 or 10mg is accompanied by a slightly increased risk of urinary tract infection. Journal of diabetes and its complications • 2013-01-15 • Meta-Analysis | N = 3,152 | 99/100 | PMID 23849632 ↗ |
| New Insights on Benefits and safety of dapagliflozin plus saxagliptin vs single-drug treatment as: What a 7,346-Participant Study Found Patients taking the DSM therapy had better effects in reducing the level of HbA1c, FPG, body weight, SBP and DBP than the DM and SM therapy. Medicine • 2020-07-24 • Meta-Analysis | N = 7,346 | 94/100 | PMID 32791755 ↗ |
| New Insights on Dapagliflozin is effective as add-on therapy to sitagliptin with or without: What a 432-Participant Study Found These results suggest that in patients with type 2 diabetes, inadequately controlled on sitagliptin with or without metformin, add-on treatment with dapagliflozin provides additional clinical benefit and is well tolerated. Diabetes care • 2014-01-15 • Randomized Controlled Trial | N = 432 | 93/100 | PMID 24144654 ↗ |
| New Insights on Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes: What a 406-Participant Study Found Despite similar 52-week glycemic efficacy, dapagliflozin reduced weight and produced less low blood sugar than glipizide in type 2 diabetes inadequately controlled with metformin. Diabetes care • 2011-09-15 • Randomized Controlled Trial | N = 406 | 93/100 | PMID 21816980 ↗ |
| New Insights on Benefits and safety of bexagliflozin compared with dapagliflozin as an add-on: What a 406-Participant Study Found Bexagliflozin showed nearly identical effects and a similar safety profile to dapagliflozin when used in Chinese patients on metformin. Journal of diabetes • 2024-04-15 • Phase III Randomized Trial | N = 406 | 93/100 | PMID 38584148 ↗ |
Dapagliflozin and Metformin Hydrochloride Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.4606/unit (~$13.82/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $66.54 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 16 Anonymous DotMD Community Micro-Logs | $27.16 / mo | View logs ↓ |
Dapagliflozin and Metformin Hydrochloride Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Dapagliflozin and Metformin Hydrochloride RxNorm Concept ID | RXN-42571322-2325 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.4606 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $66.54 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $27.16 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 78.00% Worth It (16 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Dapagliflozin and Metformin Hydrochloride Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Dapagliflozin and Metformin Hydrochloride integrating DailyMed SPL (2026-07-01), CMS NADAC ($0.4606/unit), and 16 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Dapagliflozin and Metformin Hydrochloride community threads and patient logs by age, biological sex, dosage, and treatment duration.